Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 1/2003

01.06.2003

Positron emission tomography with [18F]FDG for therapy response monitoring in lymphoma patients

verfasst von: Karoline Spaepen, Sigrid Stroobants, Gregor Verhoef, Luc Mortelmans

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Sonderheft 1/2003

Einloggen, um Zugang zu erhalten

Abstract

Lymphomas are a heterogeneous group of diseases with differing histopathology, clinical behaviour, response to therapy and outcome. Lymphomas are highly sensitive to chemotherapy and radiotherapy, and the recent developments in treatment have considerably improved clinical outcome. However, there is increasing recognition that this has been at the cost of long-term treatment-related effects in a relatively young patient population. Thus, one of the most challenging aspects in the imaging of lymphoma patients is tailoring the intensity of the treatment to the individual patient. This paper reviews recently published data concerning the use of fluorine-18 fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) for therapy monitoring in lymphoma patients and highlights the shortcomings and future directions. A temporary strategy for the implementation of [18F]FDG-PET in the management of lymphoma patients is proposed.
Literatur
1.
Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for the detection of lymphoma. J Nucl Med 1987; 28:288–292.
2.
Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 2000; 27:1564–1578.
3.
Coiffier B. How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin's lymphoma patients [editorial]? Ann Oncol 1999; 10:1141.
4.
Russel KJ, Hope RT. Response of mediastinal Hodgkin's disease to radiotherapy: rate of tumor regression not predictive of outcome. Int J Radiat Oncol Biol Phys 1989; 16:201–204.
5.
Hill M, Cunningham D, MacVicar D, et al. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol 1993; 11:2273–2278.
6.
Kaplan W, Jochelson MS, Herman TS, et al. Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 1990; 8:1966–1970.
7.
Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997; 15:1631–1637.
8.
Front D, Bar-Shalom R, Mor M, et al. Aggressive non-Hodgkin's lymphoma: early prediction of outcome with67Ga scintigraphy. Radiology 2000; 214:253–257.
9.
Zinzani PL, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999; 10:1181–1184.
10.
Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using F-18-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has a higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429–433.
11.
Maisey NR, Hill ME, Webb A, et al. Are18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer 2000; 36:200–206.
12.
Gordon L, Harrington D, Anderson J, et al. Comparison of a second-generation combination chemotherapy regimen (m-BACOP) with a standard regimen (CHOP for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327:1342–1349.
13.
Mikhaeel NG, Timothy AR, Odoherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma, comparison with CT. Leuk Lymphoma 2000; 39:543–553.
14.
Spaepen K, Stroobants S, Dupont P, et al. The prognostic value of positron emission tomography (PET) with18F-fluorodeoxyglucose (18FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: 18FDG-PET, a valid alternative to conventional diagnostic methods. J Clin Oncol 2000; 19:414–419.
15.
Juweid ME, Wiseman GA, Menda Y, Vose J, Links B, Graham MM. FDG-PET in the prediction of progression free survival at 1-year of patients with aggressive non-Hodgkin's lymphoma following antracycline based first line chemotherapy [abstract]. Eur J Nucl Med 2002; 29 (Suppl 1):S264.
16.
Aisenberg AC. Problems in Hodgkin's disease management. Blood 1999; 93:761–779.
17.
de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK.18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's disease. Ann Oncol 2001; 12:29–37.
18.
Weihrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98:2930–2943.
19.
Spaepen K, Stroobants S, Dupont P et al. Can positron emission tomography with18F-fluorodeoxyglucose (18F-FDG-PET) after first line treatment distinguish Hodgkin's disease patients who need additional therapy from others where additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115:272–278.
20.
Mikhaeel NG, Mainwaring P, Nunan T, Timothy AR. Prognostic value of interim and post treatment FDG-PET scanning in Hodgkin lymphoma [abstract]. Ann Oncol 2002; 13 (Suppl 2):21.
21.
The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329:987–994.
22.
Armitage J, Weisenburger D, Hutchins M, et al. Chemotherapy for diffuse large-cell lymphoma—rapidly responding patients have more durable remissions. J Clin Oncol 1986; 4:160–164.
23.
Thomas F, Cosset J-M, Cherel P, et al. Thoracic CT-scanning follow-up of residual mediastinal masses after treatment of Hodgkin's disease. Radiother Oncol 1988; 11:119–122.
24.
Hoekstra OS, van lingen A, Ossenkoppele GJ, et al. Early response monitoring in malignant lymphoma using fluorine-18-fluorodeoxyglucose single-photon emission tomography. Eur J Nucl Med 1993; 20:1214–1220.
25.
Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, et al. Evaluation of tumor metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995; 22:434–442.
26.
Römer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91:4464–4471.
27.
Jerusalem G, Beguin Y, Fassotte M-F, et al. Persistent tumor18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000; 85:613–618.
28.
Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13:1356–1363.
29.
Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma ad Hodgkin's disease. J Nucl Med 2002; 43:1018–1027.
30.
Lowe VJ, Wiseman GA. Assessment of lymphoma therapy using18F-FDG-PET. J Nucl Med 2002; 43:1028–1030.
31.
Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemosensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540–1545.
32.
Stiff PJ, Dahlberg S, Forman SJ, et al. Autologous bone marrow transplantation for patients with relapses or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimes. J Clin Oncol 1998; 16:48–55.
33.
Becherer A, Mitterbauer M, Jaeger U, et al. Positron emission tomography with FDG-PET predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002; 16:260–267.
34.
Filmont JE, Yap C, Emmanouilides C, et al. Prognostic value18F-FDG-PET after high-dose chemotherapy and prior to autologous stem cell transplantation in lymphoma [abstract]. J Nucl Med 2002; 43 (Suppl): 78P.
35.
Cremerius U, Fabry U, Wildberger JE, et al. Pre-transplant positron emission tomography using fluorine-18-fluoro-deoxyglucose predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 30:103–111.
36.
Schot BW, Pruim J, van Imhoff GW, Sluiter W, Vellenga E, Vaalburg W. Early FDG-PET for the prediction of long-term outcome in chemo-sensitive relapsed lymphoma [abstract]. Eur J Nucl Med 2002; 29 (Suppl 1):S113.
37.
Torizuka T, Zasadny KR, Kison PV, Rommelfanger SG, Kaminski MS, Wahl RL. Metobolic response on non-Hodgkin's lymphoma to131I-anti-B1 radioimmunotherapy: evaluation with FDG-PET. J Nucl Med 2000; 41:999–1005.
38.
Scheidhauer K, Wolf I, von Schilling C, et al. Outcome prediction of radioimmunotherapy of NHL by FDG-PET [abstract]. Eur J Nucl Med 2002; 29 (Suppl 1):S113.
39.
Hofmann M, Hertenstein B, Boerner AR, et al. 18-F-FDG PET in monitoring therapy response to RIT by 131-I rituximab antibody [abstract]. Ann Oncol 2002; 13 (Suppl 2):96.
Metadaten
Titel
Positron emission tomography with [18F]FDG for therapy response monitoring in lymphoma patients
verfasst von
Karoline Spaepen
Sigrid Stroobants
Gregor Verhoef
Luc Mortelmans
Publikationsdatum
01.06.2003
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe Sonderheft 1/2003
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-003-1166-5

Weitere Artikel der Sonderheft 1/2003

European Journal of Nuclear Medicine and Molecular Imaging 1/2003 Zur Ausgabe

OriginalPaper

PET and restaging of malignant lymphoma including residual masses and relapse

OriginalPaper

Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma

OriginalPaper

The classification of lymphomas: a new beginning or the end of an era?

OriginalPaper

PET in lymphoma: what are the oncologist's needs?

OriginalPaper

Impact of technology on the utilisation of positron emission tomography in lymphoma: current and future perspectives

OriginalPaper

Current therapies in Hodgkin's disease